SERPINE1 and pulmonary fibrosis: Of note, despite the limited published data evaluating PAI-1 inhibition in models of lung fibrosis, a phase II trial of TM5614 for the treatment of interstitial lung disease associated with systemic sclerosis is pending (jRCT2021230022).